Science. Service. Solutions.

We are a quality and innovation-led CDMO with over 25 years of experience, committed to helping our clients deliver cell and gene therapies that transform patients’ lives.

We offer end-to-end capabilities, from plasmid design and optimisation, to clinical and commercial CGMP manufacturing, accompanied by robust control systems, analytical methods and deep regulatory knowledge.

Our expertise across lentivirus, AAV, and adenoviral vectors is relied upon by some of the world’s most successful biotechnology and pharmaceutical companies.

Let's talk

>340

CGMP batches released

>50

Audits completed

>30

Process development projects

>70

Qualified assays and methods

About Oxford Biomedica

We believe in pushing the boundaries of scientific possibility and know it takes exceptional knowledge and innovative processes to make that happen.

  • 1st worldwide to administer lentiviral vector gene therapy in vivo
  • 1st commercial supplier of lentiviral vectors for a CAR-T therapy
Read more about us
OXB Manufacturing

Our cell and gene therapy services

We have extensive end-to-end capabilities in lentivirus and AAV vectors, as well as adenovirus systems and can help you design, develop, manufacture and deliver the life-changing medicines of tomorrow.

Discover our services

LentiVector® platform

Achieve reliable and impressive results with our innovative LentiVector® platform, the first commercially approved lentiviral gene delivery technology.

LentiVector® platform

AAV platform

Bring confidence to clinical trials with our proven AAV viral vector development and production process, capable of producing consistently high quality and high titre products.

We have:

  • Demonstrated >E15 vg/L titers
  • Achieved >90% fully intact vector
  • Analytical toolbox with over 45 methods
  • Process scales from 2L to 2000L
  • Six successful IND/CTA filings
AAV

Tech transferred-in

Alongside our own LentiVector® and AAV platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.

Latest news

Discover our latest updates.

Oxford Biomedica completes acquisition of ABL Europe

Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”). Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK Expands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues 3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company’s international development, manufacturing and testing presence, services and capacity by establishing a strong footprint within the European Union with facilities in Lyon and Strasbourg, France. In addition, the acquisition increases Oxford Biomedica’s capacity in process and analytical development and early- stage manufacturing across Adenovirus, Lentiviral vectors, AAVs and with this acquisition, MVA and Vaccinia. Pursuant to the transaction terms, as previously disclosed, ABL Europe has been acquired for a consideration of €15million, (including the value of €10million of pre-completion cash funding from Institut Mérieux in ABL Europe) in exchange for 3,149,374 new ordinary shares in the Company (representing 3.2 per cent of the Company’s enlarged issued share capital) which have been issued at a price of 407.4p. The shares have this morning been admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. In accordance with the terms of the transaction, Institut Mérieux intends to become a major shareholder in Oxford Biomedica and prior to today’s completion of the acquisition of ABL Europe had already built a stake of 3.3 per cent of the Company’s then issued share capital through purchases in the open market, with the intention of owning approximately 10.0 percent of the Company’s ordinary shares by the end of Q3 2024. The Company confirms that there is no material change to the 2023 financial guidance provided at the Interim Results in September previously reaffirmed in the Business Update on 7 December 2023. The Company will in due course issue medium term financial guidance to include the impact of the acquisition. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “Welcoming ABL Europe into the OXB family is an important step to unlock our ability to serve more clients with existing and new technologies, expanding development capacity, and further broadening our geographical presence. We are also delighted to have Institut Mérieux as a long-term shareholder as we continue to solidify our position as a world leading pure-play quality and innovation-led global cell and gene therapy CDMO.” Michel Baguenault, Chief Executive Officer of Institut Mérieux, said: “Institut Mérieux is delighted that ABL Europe is becoming part of OXB, a world leading cell and gene therapy CDMO. Our investment reflects our confidence in OXB’s potential to ensure ABL’s long-term development. This transaction opens up exciting growth opportunities for ABL Europe, that will significantly expand their offering to biopharma and biotech companies, and ultimately help more patients.”   -Ends-   Enquiries:  Oxford Biomedica plc:  Sebastien Ribault, Chief Commercial Officer  T: +44 (0)7519 109325 / E: partnering@oxb.com  Sophia Bolhassan, VP, Corporate Affairs and IR  T: +44 (0) 7394 562 425 / E: ir@oxb.com  ICR Consilium:  Mary-Jane Elliott / Matthew Neal / Davide Salvi  T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com    About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

Read more

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing

Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors. This event will demonstrate how unique and transferable technical expertise in viral vector development can significantly accelerate the development path and future-proof gene therapy products.  This webinar, titled “Viral Vector Manufacturing Success Stories: Onboarding to GMP Production”, will feature a presentation by:  – Amy Barker, PhD, Principal Scientist, Process Development at Oxford Biomedica,  – Andre Raposo, PhD, Director, Innovation Department at Oxford Biomedica, and  – Hannah Boss, Head of Quality Control at Oxford Biomedica.  Attendees will learn about:  Cutting-edge, end-to-end automation of analytical assays  Design of Experiments to optimize vector production  Considerations for product comparability during process changes  Case studies to demonstrate enhancements to viral vector production and successful process transfer to GMP operations  The webinar will be held at 16:00 GMT / 11:00 EST / 17:00 CET on Wednesday 7 February 2024, followed by a live Q&A session. To register for the webinar, please click here.  More information about Oxford Biomedica’s products and services can be found here.    -Ends-    About Oxford Biomedica  Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.  One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.  Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us  on LinkedIn and YouTube.    Enquiries:  Oxford Biomedica plc:  Sebastien Ribault, Chief Commercial Officer  T: +44 (0)7519 109325 / E: partnering@oxb.com  Sophia Bolhassan, VP, Corporate Affairs and IR  T: +44 (0) 7394 562 425 / E: ir@oxb.com  ICR Consilium:  Mary-Jane Elliott / Matthew Neal / Davide Salvi  T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com 

Read more

Business Update

Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing) On track to achieve 2023 guidance provided at the Interim Results and reiteration of medium term guidance; growth supported by new orders recently signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectors Progress towards multi-vector multi-site model with transfer of lentiviral vector capabilities to Bedford, Massachusetts site and acquisition of ABL Europe Recruitment of UK and US Site Heads with extensive CDMO experience to support move to site-based structure and strategic shift to a pure-play CDMO Significant progress in streamlining of operations to become a pure-play CDMO resulting in annualised cost-savings of c.£30 million   Oxford, UK – 7 December 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces a business update for the year ending 31 December 2023.   Becoming a pure-play CDMO in cell and gene therapy Oxford Biomedica has made significant progress in its streamlining of operations to become a pure-play quality and innovation-led global cell and gene therapy CDMO. The Company has concluded the reorganisation of its workforce, which, among other measures to increase efficiencies, includes a more streamlined structure across the UK and US. This organisational restructuring is tailored to boost efficiency and client-centricity, aligning roles and operations with the specific requirements of a pure-play CDMO. These strategic changes will result in a reduction of the ongoing cost base from 1 January 2024 by c.£30 million on an annualised basis compared to 2023.   Positive momentum in commercial activity The Company continues to demonstrate robust business development activity, a testament to its strong position in the viral vector space. This year, Oxford Biomedica has more than doubled the number of contracts and client orders signed compared to the previous year, reflecting a growing demand for its services from a diverse array of pharmaceutical and biotech clients. Current contracted value of client orders signed in 2023 is £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing). Furthermore, the pipeline of opportunities continues to progress as anticipated, not only in lentivirus, AAV, and adenoviral vectors but also in other vector types. Work with these additional vector types now account for more than 10% of the weighted pipeline.   Current trading and medium term guidance In line with guidance provided at the Interim Results in September, the Company is on track to deliver revenues for the year ending 31 December 2023 of approximately £90 million. Also in line with guidance provided at the Interim Results, Operating EBITDA loss for the second half of 2023 is on track to be approximately £10 million better than the first half. The Company also remains on track to deliver broadly breakeven Operating EBITDA in 2024, bolstered by positive momentum in business development activities and new orders recently secured across lentivirus, adenoviral vectors and AAV, with both new and existing clients. This momentum will further support the Company’s medium term guidance of a three-year revenue CAGR in excess of 30%, and at least a doubling of revenues by the end of 2026. The above guidance excludes the financial impact of the acquisition of ABL Europe SAS (“ABL Europe”). The Company will provide further financial guidance after the completion of this transaction, currently expected in the first quarter of 2024.   Multi viral vector CDMO capabilities across multiple sites Oxford Biomedica has achieved significant progress in transferring its lentiviral vector capabilities to its Bedford, Massachusetts site. The transfer of its 5L process is already underway. This will be followed shortly by the introduction of 7L scale and 50L pilot scale capabilities. The material produced from these pilot scale batches will be instrumental in supporting assay qualification for pre-clinical activities as well as for IND (Investigational New Drug) and IMPD (Investigational Medicinal Product Dossier) enabling studies. In October 2023, Oxford Biomedica welcomed Thierry Cournez, formerly of Merck Life Science, as Chief Operating Officer & Site Head of UK Operations, to lead the integration of Oxford Biomedica’s sites and take direct responsibility for the Company’s UK operations in Oxford. This appointment follows the earlier recruitment of Mark Caswell who brings extensive CDMO experience from his previous roles at Rentschler Biopharma and Lonza. In July 2023, he took on the role of Site Head of US Operations. The shift to a site-based structure allows the Company to maximise efficiencies as well as be better adapted to serve client’s needs. On 4 December 2023, Oxford Biomedica announced it had entered into a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe for a consideration of €15 million. This will support the future growth of all viral vector segments and allow the Company to expand its international footprint into the European Union with sites in Lyon and Strasbourg, France. Completion of the transaction is currently expected to take place in the first quarter of 2024 subject to the satisfaction and/or waiver of outstanding conditions, including obtaining the necessary regulatory approvals.   Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “Oxford Biomedica is successfully delivering on its strategic vision to become a pure-play CDMO. The streamlining of our operations has involved a strategic shift towards a CDMO mindset and we are now focused on being entirely client-centric. We remain encouraged by our increase in client orders, which have doubled since 2022 and we are now well-positioned to drive robust revenue growth while targeting broadly breakeven Operating EBITDA by the end of 2024.”   Attendance at the Annual J.P. Morgan Healthcare Conference Oxford Biomedica is attending the Annual J.P. Morgan Healthcare Conference. Frank Mathias, Chief Executive Officer, will give a presentation, which will be available on the Oxford Biomedica website after the conference at www.oxb.com/investors/results-reports-presentations-webcasts . -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

Read more

Downloads

Learn about our 4th generation lentiviral vector delivery system and how this latest lentiviral vector technology developed at Oxford Biomedica can significantly enhance the development and manufacture of safer and more effective lentiviral vector based.

 Download

You can also download brochures for our other unique technologies including our TRiP System™ and LentiStable™ cell lines here.

View all

Email alerts

Subscribe to our mailing list

Email Alerts form

Privacy policy(Required)